Predictive Accuracy of the CHA2 DS2 -VASc-HSF Score in Determining One-Year Cardiovascular Outcomes in Patients with Non-ST-Elevation Acute Coronary Syndrome: A Retrospective Study

Abstract

Introduction: To investigate the predictive accuracy of the CHA2 DS2 -VASc-HSF score in predicting the one-year mortality and major adverse cardiac and cerebrovascular events (MACCEs) in patients with non-STelevation acute coronary syndrome (NSTE-ACS). Patients and Methods: In this retrospective study, the study cohort was divided in to two groups based on the median CHA2 DS2 -VASc-HSF score: low-risk group (≤ 4 points) and high-risk group (> 4 points). Results: We enrolled 394 patients with NSTE-ACS (mean age: 58.7 ± 11.8 years). The CHA2 DS2 -VASc-HSF score independently predicted the coronary artery disease (CAD) severity (p< 0.01), one-year mortality (p< 0.01), and MACCEs (p< 0.01). The Global Registry for Acute Coronary Events (GRACE) risk score (GRS 1.0) independently predicted the CAD severity (p< 0.01), whereas the revised GRACE 2.0 risk score (GRS 2.0) independently predicted the one-year mortality (p< 0.01) and MACCEs (p< 0.01). The diagnostic performance of CHA2 DS2 -VASc-HSF was similar to GRS 2.0 in predicting the one-year mortality and MACCEs [area under the curve (AUC), 0.75 and 0.69 vs. 0.78 and 0.67; p= 0.41, p= 0.38, respectively) and better than GRS 1.0 for the CAD severity (AUC, 0.85 vs. 0.79; p= 0.03). The Kaplan-Meier curves displayed significantly higher one-year mortality and MACCEs in the high-risk group (p< 0.01) compared with the low-risk group (p< 0.01). Conclusion: The predictive accuracy of CHA2 DS2 -VASc-HSF is comparable to that of GRS 2.0 in determining the long-term cardiovascular outcomes; thus, it could be considered as a predictive model for patients with NSTE-ACS.

Keywords

• Non-ST-elevation acute coronary syndrome
• CHA2 DS2 -VASc-HSF
• GRACE risk score
• mortality

ST-Yükselmesiz Akut Koroner Sendromlu Hastalarda Bir Yıllık Kardiyovasküler Sonuçların Belirlenmesinde CHA2 DS2 -VASc-HSF Skorunun Prediktif Değeri: Retrospektif Bir Çalışma

Abstract

Giriş: Bu çalışmada esas olarak modifiye CHA2 DS2 -VASc-HSF skorunun ST-yükselmesiz akut koroner sendromlu (STYz-AKS) hastalarda bir yıllık mortalite ve majör advers kardiyak ve serebrovasküler olayları (MACCEs) öngörüp öngörmediğini araştırmayı amaçladık. Hastalar ve Yöntem: Hastane kayıtları kullanılarak tasarlanmış bu retrospektif çalışmada, çalışma popülasyonu ortanca CHA2 DS2 -VASc-HSF skoruna göre düşük (≤ 4 puan) ve yüksek riskli (> 4 puan) olarak iki gruba ayrılmıştır. Bulgular: Çalışmaya ortalama 58.7 ± 11.8 yaşında olan 394 STYz-AKS hastası dahil edilmiştir. CHA2 DS2 - VASc-HSF skoru, koroner arter hastalığı (KAH) yaygınlığının, bir yıllık mortalitenin ve MACCEs’in bağımsız öngördürücüsü olarak bulunmuştur (sırasıyla, p< 0.01, p< 0.01, p< 0.01). Ayrıca “The Global Registry for Acute Coronary Events (GRACE)” 1.0 risk skorunun KAH yaygınlığı için (p< 0.01), güncellenmiş GRACE 2.0 risk skorunun ise bir yıllık mortalite ve MACCEs için bağımsız öngördürücü olduğunu saptadık (sırasıyla, p< 0.01, p< 0.01). CHA2 DS2 -VASc-HSF ve GRACE 2.0 risk skorlarının bir yıllık mortalite ve MACCEs’i öngörmede tanısal performanları istatistiksel olarak birbirine benzer iken [eğri altında kalan alan (AUC)= 0.75 ve 0.69 vs. 0.78 ve 0.67; sırasıyla, p= 0.41, p= 0.38), CHA2 DS2 -VASc-HSF KAH şiddetini öngörmede GRACE 1.0 risk skorundan daha iyi performans sergiledi (AUCs= 0.85 vs. 0.79; p= 0.03). Kaplan-Meier eğrisi CHA2 DS2 -VASc-HSF skoru > 4 puan olan hastalarda düşük riskli hastalara göre bir yıllık mortalite ve MACCEs’in istatistiksel olarak anlamlı derecede daha yüksek olduğunu gösterdi (sırasıyla, p< 0.01, p< 0.01). Sonuç: CHA2 DS2 -VASc-HSF’nin uzun dönem kardiyovasküler sonuçları öngörmedeki doğruluğu GRACE 2.0 ile kıyaslanabilir düzeyde olup klinik uygulamada STYz-AKS hastaları için bir tahmin modeli olarak düşünülebilir.

Keywords

• ST-yükselmesiz akut koroner sendrom
• CHA2 DS2 -VASc-HSF
• GRACE risk skoru
• mortalite

References

1. 1. Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2014;64:139-228.
2. 2. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al.; ESC Scientific Document Group. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2016;37:267-315.
3. 3. Oner E, Gorgulu S, Aksu HU, Baycan OF, Erturk M, et al. GRACE and TIMI scores in predicting the extension of coronary artery disease in patients with non-ST elevation myocardial infarction. Dicle Medical Journal 2015;42:170-4.
4. 4. Roy SS, Abu Azam STM, Khalequzzaman M, Ullah M, Arifur Rahman M. GRACE and TIMI risk scores in predicting the angiographic severity of non-ST elevation acute coronary syndrome. Indian Heart J 2018;70(Suppl 3):250-3.
5. 5. Fox KAA, Fitzgerald G, Puymirat E, Huang W, Carruthers K, Simon T, et al. Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score. BMJ Open 2014;4:e004425.
6. 6. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al.; ESC Scientific Document Group. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893-962.
7. 7. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the heart rhythm society. J Am Coll Cardiol 2014;64:e1-76.
8. 8. Cetin M, Cakici M, Zencir C, Tasolar H, Baysal E, Balli M, et al. Prediction of coronary artery disease severity using CHA2DS2 and CHA2DS2-VASc scores and a newly defined CHA2DS2-VASc-HS Score. Am J Cardiol 2014;113:950-6.

9. 9. Kim KH, Kim W, Hwang SH, Kang WY, Cho SC, Kim W, et al.; Other Korean Working Group in Myocardial Infarction Registry Investigators. The CHA2DS2-VASc score can be used to stratify the prognosis of acute myocardial infarction patients irrespective of presence of atrial fibrillation. J Cardiol 2015;65:121-7.
10. 10. Keskin K, Yildiz SS, Cetinkal G, Aksan G, Kilci H, et al. The value of CHA2DS2-VASc score in predicting all-cause mortality in patients with ST-segment elevation myocardial infarction who have undergone primary percutaneous coronary intervention. Acta Cardiol Sin 2017;33:598604.
11. 11. Satilmisoglu MH, Gul M, Yildiz G, Akgul O, Kaya M, Cakmak HA, et al. Prognostic value of CHA2DS2-VASc score in patients with ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention. Acta Cardiol 2016;71:663-9.
12. 12. Modi R, Patted SV, Halkati PC, Porwal S, Ambar S, Mr P, et al. CHA2DS2-VASc-HSF score-New predictor of severity of coronary artery disease in 2976 patients. Int J Cardiol 2017;228:1002-6.
13. 13. Uysal OK, Turkoglu C, Duran M, Kaya MG, Sahin DY, Gur M, et al. Predictive value of newly defined CHA2DS2-VASc-HSF score for severity of coronary artery disease in ST segment elevation myocardial infarction. Kardiol Pol 2016;74:954-60.
14. 14. Al-shorbagy AN, Al-Cekelly MM, Dwedar AA, Soliman MH. The predictive value of newly defined CHA2DS2-VASc-HSF score for severity of coronary artery disease in non ST segment elevation myocardial infarction. Z U M J 2018;24:289-96.
15. 15. Garcia-Garcia HM, McFadden EP, Farb A, Mehran R, Stone GW, Spertus J, et al. Standardized end point definitions for coronary intervention trials: the Academic Research Consortium-2 consensus document. Circulation 2018;137:2635-50.
16. 16. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing areas under two or more correlated reciever operating characteristics curves: a nonparamentric approach. Biometrics 1988;44:837-45.
17. 17. Hudzik B, Szkodzinski J, Hawranek M, Lekston A, Polonski L, Gsior M. CHA2DS2-VASc score is useful in predicting poor 12-month outcomes following myocardial infarction in diabetic patients without atrial fibrillation. Acta Diabetol 2016;53:807-15.
18. 18. Taşolar H, Çetin M, Ballı M, Bayramoğlu A, Otlu YÖ, Türkmen S, et al. CHA2DS2-VASc-HS score in non-ST elevation acute coronary syndrome patients: assessment of coronary artery disease severity and complexity and comparison to other scoring systems in the prediction of in-hospital major adverse cardiovascular events. Anatol J Cardiol 2016;16(10):742-8.
19. 19. Scheuner MT, Setodji CM, Pankow JS, Blumenthal RS, Keeler E. General cardiovascular risk profile identifies advanced coronary artery calcium and is improved by family history. The Multiethnic Study of Atherosclerosis. Circ Cardiovasc Genet 2010;3:97-105.
20. 20. Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 2008;118:2243-51.
21. 21. Yanez ND, Burke GL, Manolio T, Gardin JM, Polak J; for the CHS Collaborative Research Group. Sibling history of myocardial infarction or stroke and risk of cardiovascular disease in the elderly: The Cardiovascular Health Study. Ann Epidemiol 2009;19:858-66.
22. 22. Narins CR, Zareba W, Moss AJ, Marder VJ, Ridker PM, Krone RJ, et al. Relationship between intermittent claudication, inflammation, thrombosis, and recurrent cardiac events among survivors of myocardial infarction. Arch Intern Med 2004;164:440-6.
23. 23. Banks E, Joshy G, Korda RJ, Stavreski B, Soga K, Egger S, et al. Tobacco smoking and risk of 36 cardiovascular disease subtypes: fatal and non-fatal outcomes in a large prospective Australian study. BMC Med 2019;17:128.
24. 24. Valerio L, Peters RJ, Zwinderman AH, Pinto-Sietsma SJ. Association of family history with cardiovascular disease in hypertensive individuals in a multiethnic population. J Am Heart Assoc 2016;5:e004260.
25. 25. Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, et al. Impact of diabetes on long-term prognosis in patients with unstable angına and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 2000;102:1014-9.
26. 26. Bahit MC, Lopes RD, Clare RM, Newby LK, Pieper KS, Van de Werf F, et al. Heart failure complicating non-ST-segment elevation acute coronary syndrome: timing, predictors, and clinical outcomes. JACC Heart Fail 2013;1:223-9.
27. 27. Bundhun PK, Wu ZJ, Chen MH. Impact of modifiable cardiovascular risk factors on mortality after percutaneous coronary intervention: a systematic review and meta-analysis of 100 studies. Medicine (Baltimore) 2015;94:e2313.
28. 28. Tamosiunas A, Radisauskas R, Klumbiene J, Bernotiene G, Petkeviciene J, Luksiene D, et al. The prognostic value of family history for the estimation of cardiovascular mortality risk in men: results from a long-term cohort study in Lithuania. PLoS One 2015;10:e0143839.
29. 29. Banks E, Joshy G, Korda RJ, Stavreski B, Soga K, Egger S, et al. Tobacco smoking and risk of 36 cardiovascular disease subtypes: fatal and non-fatal outcomes in a large prospective Australian study. BMC Med 2019;17:128.
30. 30. Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo A, Dawkins K, et al. The SYNTAX score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention 2005;1:219-27.
31. 31. El Kersh AM, Reda AA, El Hadad MG, El Sharnouby KH. Correlation between SYNTAX score and pattern of risk factors in patients referred for coronary angiography in cardiology department, Menoufia University. World J Cardiovasc Dis 2018;8:431-9.
32. 32. Montero-Cabezas JM, Karalis I, Wolterbeek R, Kraaijeveld AO, Hoefer IE, Pasterkamp G, et al. Classical determinants of coronary artery disease as predictors of complexity of coronary lesions, assessed with the SYNTAX score. Neth Heart J 2017;25:490-7.
33. 33. Otaki Y, Gransar H, Berman DS, Cheng VY, Dey D, Lin FY, et al. Impact of family history of coronary artery disease in young individuals (from the CONFIRM registry). Am J Cardiol 2013;111:1081-6.
34. 34. Sobiczewski W, Wirtwein M, Trybala E, Gruchala M. Severity of coronary atherosclerosis and stroke incidence in 7-year follow-up. J Neurol 2013;260:1855-8.
35. 35. Vuruskan E, Saracoglu E, Polat M, Duzen IV. Prediction of coronary artery disease severity in lower extremity artery disease patients: a correlation study of TASC II classification, Syntax and Syntax II scores. Cardiol J 2017;24:495-501.